Biophage announces an innovative integrated approach for the management of bacterial contamination in hospitals
Tuesday August 29, 9:00 am ET
Management of antibiotic resistance is one of the fastest growing markets in North America
MONTREAL, Aug. 29 /CNW Telbec/ - (TSX-V: BUG - News) - Biophage Pharma Inc. (TSX.V: BUG) announced today that it is developing an innovative integrated approach for the management of bacterial contamination in hospitals. The tandem development of its PDS(R) Biosensor will identify Antibiotic Resistant bacteria and the novel approaches to phage therapy will then be applied to contain these infections.
According to a new study published in the New York Journal of Medicine, Methicillin- Resistant Staph aureus (MRSA) was found in 249 of the 422 patients treated for skin infections in emergency rooms at 11 hospitals across the USA. This landmark study defines the amazing extent to which community-associated MRSA has spread throughout the U.S. population. Drug resistant bacteria that were rare just 6 years ago are now the most common cause of skin infections and are the source of an increasing public health problem in otherwise healthy people, causing serious skin infections and pneumonia.
"It is clear that the rapid containment of a bacterial infection can be achieved by accurately diagnosing the bacteria and its associated antibiotic resistance, allowing for a more precise and effective course of treatment. A timely response will almost certainly reduce mortality and morbidity rates while significantly reducing costs for the patient and the health care system," commented Dr Mandeville, President and CEO of Biophage Pharma. "Our PDS(R) Biosensor can detect clinical sensitivity to antibiotics and help physicians develop a custom-tailored treatment. Moreover, we are developing novel approaches to phage therapy with different collaborators and partners in order to contain such infections in the hospital environment," added Dr. Mandeville.
About Biophage Pharma Inc.
Biophage Pharma is a high potential, revenue-driven Canadian biotechnology company focused on the development of novel phage-based technologies for the detection and management of live pathogens. Founded in 1995, Biophage Pharma has well advanced phage therapy program for the management of bacterial infections and completed the development of its first prototype PDS(R) Biosensor which is entering in the pre-commercialization stage. Biophage also operates a profit center (Immunotox Labs) that provides services in Immunogenicity and Immunotoxicity, in Beryllium sensitivity testing and MELISA(R) testing for the detection of allergy to more than 20 different metals and a very large number of allergens like penicillin and pollens. (http://www.biophagepharma.com ; immunotoxlabs.com ).
For further information
Biophage Pharma Inc.: Rosemonde Mandeville, M.B., Ch.B., PhD, President and Chief Executive Officer, Biophage Pharma Inc., (514) 496-1488, rosemonde.mandeville@biophagepharma.com
ImmunotoxLabs, Division of Biophage Inc.: Miguel Retamal, Director, (514) 496-4508, miguel.retamal@biophagepharma.com
Renmark Financial Communications Inc., Investor Relations: Christine Stewart, cstewart@renmarkfinancial.com
Christina Lalli, clalli@renmarkfinancial.com
(514) 939-3989, (514) 939-3717 F, www.renmarkfinancial.com
Source: BIOPHAGE PHARMA, INC.; ImmunotoxLabs Division Biophage Inc. |
